Kymera in the News

Read about breakthroughs, clinical advancements, and ongoing work to develop new medicines at Kymera.

Featured Perspectives

Headshot of Karen Weisbach
March 31, 2023
Driving Culture Through Values
Karen Weisbach, PHR, Head of People + Culture
Headshot of Juliet Williams
March 1, 2023
Living Our Core Values – Pioneer: Breaking new ground with a powerful new modality
Juliet Williams, PhD, Head of Research
Headshot of Brian Albarran
April 21, 2023
Small Molecules, Big Impact: Expanding the Universe of Targets
Brian Albarran, PhD, Senior Vice President, Head of Corporate Strategy
Showing 24 news results
January 4, 2024

Endpoints News: Kymera doubles down on protein degraders for immunology, chasing Dupixent and Sotyktu

Looking to further expand the reach of protein degraders beyond cancer, Kymera Therapeutics revealed two new programs Thursday morning that it hopes will compete with some of the hottest immunology drugs on the market.

Read More
December 26, 2023

Genetic Engineering & Biotechnology News: Up-to-$2B Sanofi Collaboration Pays Off for Kymera

Through a pair of recent clinical milestones, Kymera Therapeutics continues to cash in on its up-to-$2 billion collaboration with Sanofi to develop first-in-class targeted protein degradation (TPD) therapies for patients with immune-inflammatory diseases.

Read More
December 11, 2023

BioCentury: Building on dermatology’s recent success

Once cast off by most pharmas and investors, dermatology drug development is experiencing a renaissance. A standout commercial success has put atopic dermatitis on the map. Each new psoriasis therapy is extending efficacy. And emerging drug classes are promising to expand the pool of responders, both within dermatology’s major indications and into new ones.

Read More
December 4, 2023

Nature Reviews Drug Discovery: PROTAC in clinic for autoimmune skin disease

The kinase IRAK4 is a crucial regulator of signalling pathways that control innate immunity. Inhibitors of its kinase activity have been developed for autoimmune diseases but have not shown strong efficacy. Now, in Nature Medicine, Ackerman et al. describe an IRAK4 protein degrader and report encouraging preliminary results in patients with chronic inflammatory skin diseases.

Read More
November 29, 2023

Boston Globe: Top Places to Work in Massachusetts 2023

Nearly 76,000 workers at 347 companies responded to the survey questions rating their employers on leadership, values, training, benefits, and other metrics. The rankings are broken down into four size categories: small (50-99 employees); medium (100-249); large (250-999); and largest (1,000 or more).

Read More
November 28, 2023

Drug Hunter: KT-474 Brings IRAK4 Back: The First Clinically Active Bifunctional Degrader Outside Oncology

Kymera’s KT-474 is the first oral degrader to demonstrate activity in clinical trials outside cancer. Sanofi recently started a Ph. II trial with the molecule in AD, restoring life to IRAK4 as an immunology target.

Read More
November 20, 2023

Dermatology News: KT-474 Demonstrates Efficacy and Promise in Atopic Dermatitis and Hidradenitis Suppurativa Study

Kymera Therapeutics recently shared promising results from the phase 1 clinical trial of its lead program, KT-474, marking a significant milestone in the field of targeted protein degradation (TPD).

Read More
November 20, 2023

C&EN: Degrader progresses in clinical trials for skin conditions

Kymera Therapeutics’ degrader KT-474 has shown promise for treating two inflammatory skin conditions in an early clinical trial. The success suggests that these compounds could be used to treat nonlethal, chronic conditions, where there is a high bar for tolerability.

Read More
October 21, 2023

Talking Biotech: Therapeutics Controlling Protein Turnover – Dr. Juliet Williams

Cells have intricate mechanisms to remove damaged or mis-expressed proteins that could be deleterious to cellular function. This process is mediated by a process called ubiquitination, mediated by a special class of proteins called E3 ligases. Ubiquitin is the tag that’s added that signals that a protein should be moved to the biochemical garbage can. Dr. Juliet WIlliams of Kymera describes how their company has used modeling and A.I. to design molecular linkers that connect a protein that needs to be degraded with the machinery to tag it for destruction.

Read More
September 21, 2023

Watertown News: Watertown Life Science Company Entering Team in Jimmy Fund Walk

The company has a program called Kymera Cares, an effort that allows employees to give back, volunteer, and fundraise for organizations helping local communities throughout the greater Boston area as well as patients and their support systems.

Read More

CONTACT
PRESS RELEASES
COMPANY BACKGROUND

Featured Presentations & Publications

December 10, 2023
Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
American Society of Hematology (ASH) Annual Meeting and Exposition 2024
November 14, 2023
IRAK4 Degradation vs Inhibition
IRAK4 Program Background
November 13, 2023
Nature Medicine: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, Howard Schwartz, Brian J. Feinstein, et al.